SOLIRIS® (eculizumab) Referral Form

Patient Preferred Clinic (select one):

Texas: 469-340-0044

Oklahoma: 918-770-4421



PATIENT INFORMATION		Referral Status:	New Referral	Updated Orde	er Order Renewal
DOB: Patient Name:				Patient Phone:	
Patient Address:				Patient Email:	
NKDA Allergies:			Weig	ht (lbs/kg):	Height:
ICD-10 code (required):	ICD-10 description:		Last Treatment D	ate:	Last 4 SSN:
PROVIDER INFORMATION					
Referral Coordinator Name:		Referral Coord	Referral Coordinator Email:		
Ordering Provider:		Provider NPI:			
Referring Practice Name:		Phone:		Fax:	
Practice Address:		City:		State:	Zip Code:
NURSING Infusion to be administered per VIVO protocols. LABORATORY ORDERS CBC At each dose Every CMP At each dose Every CRP At each dose Every OTHER		Initia — 900m — week	PNH DIAGNOSIS Dosing: 600mg IV weekly for the first 4 weeks, followed by g IV for the fifth dose 1 week later, then 900mg IV every 2 thereafter enance Dose: 900mg IV every 2 weeks x 1 year		
REQUIRED DOCUMENTATION		aHUS, gMG, and NMOSD DIAGNOSIS			
Patient Demographics Insurance Card/Information Progress Notes Supporting DX Current Medication List and H&P MG-ADL Score Positive AQP4 Patient has had the meningococcal vaccines (both MenACWY and MenB) MenACWY and MenB) MGFA Classification Complete Metabolic Panel Positive AchR (gMG)		es (both week) Main	ial Dosing: 900mg IV weekly for the first 4 weeks, followed by 00mg IV for the fifth dose 1 week later, then 1200mg IV every 2 eks thereafter intenance Dose: 1200mg IV every 2 weeks		
*Consider administering premedication	for prophylaxis against infus	sion reactions and hypersensitivit	ry reactions. **Order	is valid for one y	rear unless otherwise noted**
Provider Name (Print) Provide		rovider Signature			Date
Colorado: 303-418-4679 Ne	evada: 702-489-5744 ew Jersey: 609-955-3711 nio: 216-400-0674	Massachusetts: 203-724-4838 Pennsylvania: 215-399-9244 New York: 203-724-4838	Have	Have a Question? (720) 902-4111	

Connecticut: 203-724-4838